Skip to content

Artificial Intelligence | May 11–13, 2020 | Boston, MA USA

Agenda

Monday, April 8, 2019

7:00 am - 8:00 am
7:00 am - 5:00 pm
8:00 am - 9:40 am
Bayer Ballroom

First Look: Round 1

Nine rapid fire presentations on the applications of AI in Clinical Care

To view speakers and topics, click here.

Moderator: Giles Boland, MD
  • Chair, Department of Radiology, BH; Philip H. Cook Professor of Radiology, HMS
Moderator: Trung Do
  • VP, Business Development, Innovation, PHS
9:40 am - 9:55 am
9:55 am - 11:35 am
Bayer Ballroom

First Look: Round 2

Nine rapid fire presentations on the applications of AI in Clinical Care

To view speakers and topics, click here.

11:30 am - 11:45 am
11:45 am - 1:00 pm

Discovery Café Sessions

Lunch with Experts: Intensive sessions addressing cutting-edge artificial intelligence topics.

Applying AI to Save Lives During the Opioid Crisis

The U.S. is in the throes of a devastating epidemic of opioid addiction and overdose — some 130 people die nationally every day from opioids, says the National Institute on Drug Abuse. With a total economic cost of more than $78 billion a year, AI is being harnessed to develop new tools that can help alleviate this national crisis. This session will discuss AI-based strategies that academic and industry teams are leveraging to help clinical and public health officials better predict, identify, and treat opioid addiction, and also data privacy concerns.

Moderator: Thomas Sequist, MD, Chief Quality & Safety Officer, PHS

Bob Burgin, CEO, Amplifire Healthcare Alliance

Carm Huntress, CEO, RxRevu Inc

Sarah Wakeman, MD, Medical Director, Substance Use Disorder Initiative, MGH; Assistant Professor, Medicine, HMS

Scott Weiner, MD, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program, BH; Assistant Professor, HMS

 

Community Hospitals: Key Component in Healthcare Transformation

Community hospitals are the largest sources of patient care in the U.S. As such, they represent a frontier in the transformation of health care. How are these organizations using AI and digital technologies to drive transformation? What are the distinctions from academic medical centers? This session will address these and other topics that impact community hospitals.

Moderator: Michael Jaff, DO, President, NWH, PHS, Professor of Medicine, HMS

Fabien Beckers, PhD, CEO, Arterys

Joanna Geisinger, CEO, TORq Interface

John Miller, MD, Director, Retinal Imaging, MEE; Assistant Professor, Ophthalmology, HMS

Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Professor, Neurology, HMS

Tal Wenderow, CEO, Beyond Verbal

 

Digital Management of Diabetes

Across the spectrum of patient care, the management of diabetes has been flooded with new technology and treatment options for both type 1 and type 2 diabetes – there is a range of new devices and software, including automatic insulin infusion systems, glucose sensors, AI-based algorithms and decision support tools, with an artificial pancreas on the horizon. This session will focus on these areas and clinical use cases that highlight the value of AI.

Moderator: Deborah Wexler, MD, Clinical Director, Diabetes Center, MGH; Associate Professor, HMS

Marie McDonnell, MD, Section Chief and Director, Diabetes Program, BH; Lecturer, HMS

Michael Meissner, PhD, CTO and VP, MED, Sanofi

Joshua Riff, MD, CEO, Onduo

Marie Schiller, VP, Connected Care and Insulins Product Development and Site Head, Cambridge Innovation Center, Eli Lilly

 

AI and Its Impact on the Future of Emergency Care

There are over 136 million Emergency Department visits annually in the U.S. providing 24/7 unscheduled treatment for problems from minor illness to life threatening traumatic injuries.  Emergency department care teams provide high quality, safe care in an efficient fashion.  In this session, we consider the future of AI in emergency care from the initial decision to seek emergency care, to diagnostic processes within the ED and final disposition decision..  From chat bots for patient triage, telehealth for patient visits to machine learning outcome prediction, we will consider how these novel technologies will impact emergency care delivery.

Moderator: Adam Landman, MD, VP and CIO, BH; Associate Professor of Emergency Medicine, HMS

Peter Chai, MD, Assistant Professor, Emergency Medicine, BH, HMS

Emily Hayden, MD, Attending Physician, Emergency Medicine, MGH; Instructor, Surgery, HMS

Kohei Hasegawa, MD, Attending Physician, Emergency Medicine, MGH; Associate Professor, Emergency Medicine, HMS

Sean Kelly, MD, CMO, Imprivata; Assistant Professor, Emergency Medicine, HMS

Bijoy Sagar, VP, Chief Digital Technology Officer, Stryker 

 

Mental Health, Smartphone Apps and the Promise of AI

Patients can face significant barriers when it comes to accessing high-quality, evidence-based treatment for mental illness. AI-enabled technologies, including smartphone-based tools, that may help close this treatment gap for patients worldwide. This session will focus on efforts to develop smartphone apps and other tools, including those designed to help predict patients’ moods and provide cognitive behavioral therapy.

Moderator: Sabine Wilhelm, PhD, Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, Psychology, HMS

Jennifer Gentile, PsyD, SVP, US Clinical Operations, Ieso Digital Health

Thomas McCoy, MD, Director of Research, Center for Quantitative Health, MGH; Assistant Professor, Psychiatry and Medicine, HMS

Christopher Molaro, CEO, Neuroflow

David Silbersweig, MD, Chairman, Department of Psychiatry, BH; Stanley Cobb Professor of Psychiatry, HMS

Jeremy Sohn, VP, Global Head of Digital Business Development and Licensing , Novartis

 

From Startup to Impact (Pharma and Diagnostics)

This session will introduce you to five leading start-up companies who will each share their respective impact in the pharmaceutical and diagnostic realms in 10-minute pitches.

Moderator: James Brink, MD, Radiologist-in-Chief, MGH; Juan M. Taveras Professor of Radiology, HMS

Moderator: James Nicholls, Managing Director, Fitzroy Health

Sarah Beeby, EVP, GM Lifesciences, Clinithink

Charles Cadieu, PhD, CEO, Bay Labs

JB Michel, PhD, SVP Data Science & GM USA, BenevolentAI

Art Papier, MD, CEO, VisualDx

Alex Zhavoronkov, PhD, CEO, Insilico Medicine, Inc

1:00 pm - 1:15 pm
1:15 pm - 1:30 pm
Bayer Ballroom

Opening Remarks

  • Interim President and CEO, Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, HMS; 2019 Forum Co-Chair
1:30 pm - 2:00 pm
Bayer Ballroom

AI Strategy: AI from the Top

As the potential of AI comes into clearer view, many academic medical centers are taking notice and crafting institutional strategies for incorporating AI into clinical practice. But where are the most meaningful opportunities? What are the biggest challenges? And, importantly, will patient care be noticeably different — better, more available, and/or less costly?

  • Board Member, PHS; President Emerita and Professor of Neuroscience, MIT
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
  • Chief Digital Health Officer, PHS
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2019 Forum Co-Chair
2:00 pm - 2:30 pm
Bayer Ballroom

1:1 Fireside Chat: Jensen Huang, CEO, NVIDIA

Introduction by: Cathy Minehan
  • Managing Director, Arlington Advisory Partners; Chairman, Board of Trustees, MGH
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
  • CEO, NVIDIA
2:30 pm - 2:45 pm
Bayer Ballroom

Remarks: The Honorable Charlie Baker

Introduction by: Scott Sperling
  • Co-President, Thomas H. Lee Partners; Chairman of the Board of Directors, PHS
  • Governor of the Commonwealth of Massachusetts
2:45 pm - 3:35 pm
Bayer Ballroom

RWE and Trial Optimization in the AI Era

AI is a tool for conducting faster, more efficient clinical trials. Panelists will discuss how AI-enabled methods can further adaptive trial capabilities, trial design and trial management.

Moderator: Thomas Lynch, MD
  • EVP and CSO, R&D, Bristol-Myers Squibb
  • Deputy Commissioner, FDA
  • EVP MA&PV and Bayer CMO, Bayer AG
  • Chief Architect, Microsoft Healthcare
  • CEO, My Own Med Inc.
  • Executive Director, Clinical Trials Office, PHS; Associate Professor of Medicine, HMS
3:35 pm - 4:25 pm
Bayer Ballroom

AI Driven Value-Based Care

As providers embrace value-based approaches, the demands of clinical data collection, assessment, and information-sharing loom large. In this data-driven environment, clinicians must sift through ever-growing pools of information that can exceed the limits of human capability. An assortment of AI-based solutions is now emerging that may offer some relief. Panelists will discuss how these approaches are helping to support better, more personalized care, and the challenges faced by clinicians and managers for effective adoption.

  • CEO, MGPO; Professor of Medicine, HMS
  • CEO, American Heart Association
  • EVP, President, Network Solutions, Change Healthcare
  • CEO, NHS England
4:25 pm - 5:15 pm
Bayer Ballroom

Cardiovascular Care: Reinvented Through AI

Cardiovascular diseases remain the leading cause of death worldwide and an expense, making this area ripe for AI-enabled innovations. Teams are pursuing a range of AI-based tools in cardiovascular medicine: including AI-powered drug discovery and diagnostics to automated cardiac image analyses and AI-guided care delivery pathways. Panelists will discuss where AI is having a sizeable impact. The discussion will also include the perspectives of a patient who benefited from AI-enabled cardiovascular care.

  • Vice Chair for Scientific Innovation, Department of Medicine, BH; Associate Professor of Medicine, HMS
  • SVP, Global Head of Digital and Analytics, Sanofi
  • Patient
  • Independent Recording Engineer Burke Recording
  • President, Bayer Pharma Americas Region, Bayer
  • Chief Cardiovascular Imaging, MGH; Professor, Radiology, HMS
  • EVP/GM, Healthcare and Life Sciences, Persistent Systems
5:15 pm - 5:45 pm
Bayer Ballroom

1:1 Fireside Chat: Seema Verma, Administrator, Centers for Medicare & Medicaid Services

  • Chief Population Health Officer, PHS; Assistant Professor, Medicine, HMS
  • Administrator, Centers for Medicare and Medicaid Services
5:45 pm - 6:45 pm

Tuesday, April 9, 2019

7:00 am - 8:00 am
7:00 am - 5:00 pm
7:40 am - 7:50 am
Bayer Ballroom

Opening Remarks

  • Chief Innovation Officer, PHS; President, Partners HealthCare International
7:50 am - 8:40 am
Bayer Ballroom

Implementing AI in Cancer Care

With AI-enabled care strategies and digital technologies, clinicians and patients are embracing new approaches to improve the lives of cancer patients through enhanced diagnosis and treatment. These include AI-guided tools for more precise methods of predicting risk, more effective screening strategies, patient data driven insights  and more personalized treatments. Panelists will engage on how these and other innovations are enabling a new era of cancer care.

  • Chief, Breast Imaging Division, MGH; Professor of Radiology, HMS
  • President and Co-Founder, LunaDNA
  • Delta Electronics Professor, Electrical Engineering and Computer Science Department, MIT
  • Director, Cancer Genome Analysis, Broad Institute; Professor, Pathology, HMS
  • CEO, insitro
8:40 am - 9:30 am
Bayer Ballroom

Imagining Medicine in the Year 2054

In 1984 Isaac Asimov was asked to predict what life in 2019 would be like. Using the same aperture, we as what will constitute health care 35 years from now? Current trends suggest that there will be significant gains in immunotherapy, gene therapy, and breakthrough treatments for neurologic, cardiovascular and oncologic diseases. Panelists will draw on their visionary perspective and will reflect on what to expect and why.

  • Director, Clinical Research, Cancer Center, MGH; Professor of Medicine, HMS
  • CEO, Flagship Pioneering
  • Vice Chair for Scientific Innovation, Department of Medicine, BH; Associate Professor of Medicine, HMS
  • Director, Cellular Immunotherapy Program, Cancer Center, MGH; Assistant Professor, Medicine, HMS
  • Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
9:30 am - 9:50 am
9:50 am - 10:15 am
Bayer Ballroom

1:1 Fireside Chat: Ash Carter, U.S. Secretary of Defense (2015 – 2017)

Moderator: Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2019 Forum Co-Chair
  • U.S. Secretary of Defense (2015–2017)
10:15 am - 10:40 am
Bayer Ballroom

1:1 Fireside Chat: Honorable Alex Azar II, Secretary of Health and Human Services

Moderator: Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2019 Forum Co-Chair
  • Secretary of Health and Human Services
10:40 am - 11:30 am
Bayer Ballroom

CEO Roundtable

Chief executives share perspectives on the impact of AI on their respective companies and industry segments. Panelists will discuss their views of AI, how AI figures into their organizations’ current product and investment strategies, and how they are measuring return on existing AI investments. The panel will also address opportunities and challenges surrounding AI, ranging from workforce needs to managing bias in AI development.

  • Interim President and CEO, Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, HMS; 2019 Forum Co-Chair
  • CEO, Philips
  • EVP, Head, Pharmaceuticals Research and Development, Bayer AG
  • CEO, Siemens Healthineers
  • CEO, GE Healthcare
11:30 am - 11:35 am
Bayer Ballroom
11:35 am - 11:45 am
11:45 am - 1:00 pm

Discovery Cafe Sessions

Lunch with Experts: Intensive sessions addressing cutting-edge artificial intelligence topics.

Provider Back Office of the Future

The application of AI-based technologies to the business side of health care — including functions such as billing, payment, and insurance claims management — could lead to significant improvements in health care operations and efficiency, with billions of dollars in savings each year. Panelists will discuss emerging tools and technologies as well as the opportunities and pitfalls of using AI to innovate and automate back office functions.

Moderator: Peter Markell, EVP, Administration and Finance, CFO and Treasurer, PHS

Ingeborg Garrison, CNO/VP of Strategic Advisory Services, Verge Health

Kent Ivanoff, CEO, VisitPay

Mary Beth Remorenko, VP, Revenue Cycle Operations, PHS

Brian Robertson, CEO, VisiQuate

 

Chief Digital Strategy Officer Roundtable

With the advent of AI-enabled technologies, this session brings together leading chief digital health officers. The discussion will address tradeoffs in sequencing technology across academic medical centers; what technologies are being prioritized; and consumer expectations.

Moderator: Alistair Erskine, MD, Chief Digital Health Officer, PHS

Michael Anderes, Chief Innovation and Digital Health Officer, Froedtert Health; President, Inception Health

Adam Landman, MD, VP and CIO, BH; Associate Professor of Emergency Medicine, HMS

Aimee Quirk, CEO, innovationOchsner

Richard Zane, MD, Chief Innovation Officer, UCHealth; Professor and Chair,Department of Emergency Medicine, University of Colorado School of Medicine

 

Innovation Fellows: A New Model of Collaboration

The Innovation Fellows Program provides experiential career development opportunities for future leaders in health care. It facilitates personnel exchanges between Harvard Medical School staff from Partners’ hospitals and participating biopharmaceutical, device, venture capital, digital health, payor and consulting firms. Fellows and Hosts learn from each other as they collaborate on projects ranging from clinical development to digital health and artificial intelligence. Learn how this new model of collaboration can deliver value and lead to broader relationships between industry and academia.

Moderator: Seema Basu, PhD, Market Sector Leader, Innovation, PHS

Nathalie Agar, PhD, Research Scientist, Neurosurgery, BH; Associate Professor, Neurosurgery, Radiology, HMS

Paul Anderson, MD, PhD, Chief Academic Officer, BH; SVP, Research, BH; K. Frank Austen Professor of Medicine, HMS

Laurie Braun, MD, Partners Innovation Fellow, MGH and Boston Pharmaceuticals; Instructor in Pediatrics, HMS

David Chiang, MD, PhD, Research Fellow, BH; Innovation Fellow, Boston Scientific

David Feygin, PhD, Chief Digital Health Officer, Boston Scientific

Peter Ho, MD, PhD, CMO, Boston Pharmaceuticals

Harry Orf, PhD, SVP, Research, MGH; Principal Associate, HMS

 

Last Mile: Fully Implementing AI in Healthcare

This session will focus on how radiology and pathology specialties are currently applying AI in the clinic. Where will it be built out first? What are the barriers and how will these challenges be overcome?

Moderator: Keith Dreyer, DO, PhD, Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS

Katherine Andriole, PhD, Director of Research Strategy and Operations, MGH & BWH CCDS; Associate Professor, Radiology, HMS

Samuel Aronson, Executive Director, IT, Personalized Medicine, PHS

Peter Durlach, SVP, Healthcare Strategy & New Business Development, Nuance

Seth Hain, VP of R&D, Epic

Jonathan Teich, MD, PhD, Chief Medical Information Officer, InterSystems; Emergency Medicine, BH

 

Reimagining Disease Management

The management of disease has become vastly more challenging, both for patients and providers. AI-based technologies promise to improve and streamline patient care through a variety of approaches. This session will feature a discussion of these new tools and how they can enhance patient engagement and optimize care management.

Moderator: Sree Chaguturu, MD, Chief Population Health Officer, PHS; Assistant Professor, Medicine, HMS

Murray Brozinsky, Chief Strategy Officer, Conversa

Jean Drouin, MD, CEO, Clarify Health Solutions

Julian Harris, MD, President, CareAllies

Erika Pabo, MD, Chief Health Officer, Humana Edge; Associate Faculty, Ariadne Labs; Associate Physician, BH; Instructor, HMS

 

Standards and Regulation: The Emerging AI Framework

As the health care industry faces an explosion of AI-based tools, the FDA’s approach to these technologies is evolving. This session will focus on the agency’s approach to AI-based products, how to calculate the risk profile of these new technologies, and the challenges of securing adequate data rights.

Moderator: Brent Henry, Member, Mintz Levin

Bethany Hills, Member/ Chair, FDA Practice, Mintz Levin

Michelle McMurry-Heath, MD, PhD, VP, Global Regulatory Affairs and International Clinical Evidence, Johnson & Johnson Medical Devices

Bakul Patel, Associate Director, Digital Health, FDA

Michael Spadafore, Managing Director, Sandbox Industries

 

From Startup to Impact (Provider Solutions)

This session will introduce you to five leading startup companies who will each share their respective impact in delivery provider solutions in ten-minute pitches.

Moderator: Meredith Fisher, PhD, Partner, Partners Innovation Fund, PHS

Moderator: James Stanford, Managing Director, Fitzroy Health

William Grambley, COO, AllazoHealth

Gal Salomon, CEO, CLEW

Brian Symmons, COO, Gauss Surgical

Pelu Tran, CEO, Ferrum Health

Ed Zecchini, CIO, Remedy Partners

1:00 pm - 1:10 pm
1:10 pm - 2:00 pm
Bayer Ballroom

China: AI Enabled Healthcare Leadership

China’s health care system faces major challenges — and its population is aging more rapidly than nearly every other country. To help address these problems, the Chinese health technology sector is strongly embracing AI. What are the most exciting applications? What lessons does China’s early forays into AI-enabled patient care hold for other health care systems?

  • President, Novartis Institutes for BioMedical Research
  • Chief Innovation Officer, GE Healthcare
  • CEO, Infervision
  • Chairman and Co-Founder, Yidu Cloud
  • Managing Partner, Qiming Venture Partners
  • CEO, Real Doctor Corporation Limited
2:00 pm - 2:30 pm
Bayer Ballroom

1:1 Fireside Chat: Mark Benjamin, CEO, Nuance

Moderator: Peter Slavin, MD
  • President, MGH; Professor, Health Care Policy, HMS
  • CEO, Nuance Communications
2:30 pm - 3:00 pm
3:00 pm - 3:50 pm
Bayer Ballroom

Getting to the AI Investment Decision

The billions invested worldwide in AI-based health care technologies underscore the enthusiasm of global investors. But where are the greatest opportunities and what is the timeline to meaningful impact? In this panel, venture, private equity investors, and buy side analysts will discuss investment priorities, timelines, and key areas of interest

  • Partner, Partners Innovation Fund, PHS
  • VP, Venture and Managing Partner, Partners Innovation Fund, PHS
  • Managing Director, Bain Capital Life Sciences
  • Managing Partner, Polaris Partners
  • SVP, Strategy, Commercialization and Innovation, Amgen
  • Managing Director, Healthcare Group, Goldman Sachs
  • Partner, GV; Instructor in Medicine, BH
3:50 pm - 4:20 pm
Bayer Ballroom
4:20 pm - 5:10 pm
Bayer Ballroom

Consumer Healthcare and New Models of Care Delivery

Al is powering a revolution in consumer health care, giving patients a deeper role in monitoring their own health and spawning new models of care delivery. Many health care organizations are increasingly focused on creating a digital “front door” for patients – a single gateway to mobile apps and other online services. Panelists will also discuss the role of remote monitoring and virtual care programs as well as the role of Al in care redesign and workflow.

Moderator: Diana Nole
  • CEO, Wolters Kluwer Health
  • President, Global Strategy Group, Samsung; Founder, CareVisor
  • VP and Global CTO, Sales, Dell EMC
  • President, Health Platforms, Verily Life Sciences
  • VP and Chief Health Officer, IBM Corporation
  • SVP, Head of Innovation and Health Equity, Microsoft Healthcare
5:15 pm - 5:25 pm
Bayer Ballroom
5:30 pm - 6:30 pm

Wednesday, April 10, 2019

7:00 am - 12:00 pm
7:30 am - 9:30 am
Bayer Ballroom

Innovation Discovery Grant Awardee Presentations

Eleven clinical teams selected to receive highly competitive Innovation Discovery Grants present their work illustrating how AI can be used to improve patient health and health care delivery. This session is designed for investors, entrepreneurs, investigators, and others who are interested in commercializing AI opportunities that are currently in development with support from the Innovation Office.

To view speakers and topics, click here.

Moderator: David Louis, MD
  • Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, HMS
  • Vice-Chair, Radiology Research, BH; Ferenc Jolesz MD Professor of Radiology, HMS
9:30 am - 10:00 am
10:00 am - 10:30 am
Bayer Ballroom

1:1 Fireside Chat: Stefan Oelrich, Member of the Board of Management; President, Pharmaceutical, Bayer AG

Introduction by: John Fish
  • CEO, Suffolk; Chairman of Board Trustees, Brigham Health
Moderator: Betsy Nabel, MD
  • President, Brigham Health; Professor of Medicine, HMS
  • Member of the Board of Management, Bayer AG; President, Pharmaceutical, Bayer AG
10:30 am - 11:00 am
Bayer Ballroom

1:1 Fireside Chat: Deepak Chopra, MD, Founder, The Chopra Foundation

  • Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
  • Founder, The Chopra Foundation
11:00 am - 11:50 am
Bayer Ballroom

Using AI to Predict and Monitor Human Performance and Neurological Disease

In the quest for effective treatments aimed at devastating neurological diseases like Alzheimer’s and ALS, there is a critical need for robust methods to predict and monitor disease progression. AI-based approaches offer promise in this important area. Panelists will discuss efforts to map movement-related disorders and use machine learning to predict the path of disease with imaging and biomarkers.

  • Chief of Neurology, Co-Director, Neurological Clinical Research Institute, MGH; Julieanne Dorn Professor of Neurology, HMS
  • Chief Scientist, Dolby Laboratories
  • VP, Clinical and Computational Neuroscience, AiCure; Assistant Professor, Psychiatry, NYU School of Medicine
  • Global Therapeutic Head, Neuroscience Janssen Research & Development
  • EVP and CMO, Biogen
11:50 am - 12:50 pm
Bayer Ballroom

Disruptive Dozen: 12 Technologies that will reinvent AI in the Next 12 Months

The Disruptive Dozen identifies and ranks the AI technologies that Partners faculty feel will break through over the next year to significantly improve health care.

  • Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, HMS
  • Associate Chief, Infection Control Unit, MGH; Assistant Professor, Medicine, HMS
1:00 pm - 1:10 pm
Bayer Ballroom
Scroll To Top